Erste Group Bank Comments on Gilead Sciences FY2027 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Stock analysts at Erste Group Bank boosted their FY2027 earnings per share (EPS) estimates for Gilead Sciences in a research report issued on Thursday, October 8th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings per share of $9.90 for the year, up from their prior estimate of $9.88. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.47) per share.

Other research analysts have also issued reports about the stock. Barclays lowered their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Truist Financial lifted their price target on shares of Gilead Sciences from $150.00 to $158.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Bank of America reiterated a “buy” rating and set a $164.00 price target on shares of Gilead Sciences in a research report on Monday. Zacks Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Finally, Royal Bank Of Canada upped their price target on Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $159.33.

Gilead Sciences Stock Down 0.5%

Shares of NASDAQ GILD opened at $150.43 on Tuesday. The stock has a market capitalization of $186.53 billion, a price-to-earnings ratio of -56.34 and a beta of 0.31. Gilead Sciences has a 52 week low of $114.02 and a 52 week high of $157.29. The firm has a 50-day moving average price of $145.51 and a 200 day moving average price of $136.80. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.01 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of GILD. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $25,000. Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,000. Kimelman & Baird LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,000. Wealth Preservation Advisors LLC raised its position in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the period. Finally, Wiser Advisor Group LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $30,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 105,000 shares of company stock worth $14,940,540 in the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend was Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is presently -122.85%.

About Gilead Sciences

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.